

P1.032: Optimizing Lung Nodule Management in Lung Cancer Screening: Impact of a Tiered Review Model



Annie D. Lu, Anil Vachani, K. Alisa Braithwaite, Melissa Morgan-Noble, Daniel H. Sterman, Jorge Mercado, Maria Banvard
NYU Langone Lung Cancer Screening Program, Perlmutter Cancer Center, New York, NY, USA
Correspondence: Annie.Lu@NYULangone.org



IASLC 2026 World
Conference on Lung Cancer
SEPTEMBER 12 - 15, 2026
SEOUL, REPUBLIC OF KOREA

INTRODUCTION

Management of positive findings is a critical component of lung cancer screening (LCS). As screening volume increased, we developed a revised workflow to more efficiently triage probably benign and suspicious pulmonary nodules.

We evaluated the impact of reassigning probably benign **Lung-RADS 3** findings from the **Lung Nodule Review Board (LNRB)**, a multidisciplinary specialists conference initially setup to review Lung-RADS 3, 4A, 4B, and 4X to the **Case Review Conference (CRC)**, a structured review process with pulmonologists and Nurse Practitioners for lower-risk findings.

METHODS

A quality improvement project.

Retrospective multicenter review of screening chest CTs from April 2025 to January 2026, with **Lung-RADS 3** cases managed through CRC review.

Outcomes measures:


- Incidence of volume reduction & case escalation
- Interval nodule worsening
- Number of Lung cancers detected

DISCUSSION AND CONCLUSION

De-escalating probably benign Lung-RADS 3 nodules from LNRB to CRC improved efficiency without compromising safety.

Future Directions:

- Refine CRC-to-LNRB escalation criteria
- Identify specific imaging features warranting intensified evaluation
- Assess cost-effectiveness and scalability across health systems




REFERENCE


American College of Radiology Committee on Lung-RADS®. Lung-RADS Assessment Categories 2022. Available at <https://www.acr.org/-/media/ACR/Files/RADS/Lung-RADS/Lung-RADS-2022.pdf>. Accessed on July 7, 2026.

RESULTS

A total of 8,369 screening chest CT scans were performed over a 9-month period.



LNRB case volume decreased by 55% after reassigning 407 Lung-RADS 3 cases to CRC: Reduced from 737 to 330 cases.



The case escalation rate from CRC to LNRB was 2.5% (10 cases).

There were 46 lung cancers diagnosed.

Among the escalated Cases:

- No cancers were identified
- No interval nodule worsening on short-term follow-up

